A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Condition:   Sarcoma, Ewing Intervention:   Biological: TK216+Vincristin Sponsor:   Shanghai Pharmaceuticals Holding Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2021 Category: Research Source Type: clinical trials